Everything below concerns thymosin beta-4. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-25. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
| Property | Value | Notes |
|---|---|---|
| Reconstitution solvent | Sterile water or aqueous buffer | Aseptic technique recommended |
| Post-reconstitution storage | 2–8 °C short term; frozen for longer periods | Avoid repeated freeze-thaw cycles |
| Typical purity assay | Reversed-phase HPLC | Peak area used to estimate purity |
| Identity confirmation | Mass measurement | Compares observed value with expected mass |
| Main degradation routes | Hydrolysis and oxidation | Accelerated by heat and extreme pH |
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
A comparative genomic analysis of 494 complete Pseudomonas genomes, including 189 complete P. aeruginosa genomes, identified several proteins that are shared by the vast majority of P. aeruginosa strains, but are not observed in other analyzed Pseudomonas genomes. These P. aeruginosa-specific core genes, such as cntL, cntM, plcB, acp1, mucE, srfA, tse1, tsi2, tse3, and esrC are known to play an important role in this species' pathogenicity.
Proteolytic venom dismantles the molecular surroundings, including at the site of the bite. Hemotoxic venom acts on the cardiovascular system, including the heart and blood. Neurotoxic venom acts on the nervous system, including the brain. Cytotoxic venom has a localized action at the site of the bite. Myotoxic venom acts on the muscular system.
== Historical background == For almost 50 years molecular biology was based on two dogmas: (i) equating biological function of the protein with a unique three-dimensional structure and (ii) assuming exquisite specificity in protein complexes. Specificity/selectivity is ensured by unambiguous set of interactions formed between the protein and its ligand (another protein, DNA, RNA or small molecule). Many protein complexes however, contain functionally important/critical regions, which remain highly dynamic in the complex or adopt different conformations. This phenomenon is defined fuzziness. The most pertinent example is the cyclin-dependent kinase inhibitor Sic1, which binds to the SCF subunit of Cdc4 in a phosphorylation dependent manner. No regular secondary structures are gained upon phosphorylation and the different phosphorylation sites interchange in the complex.
=== Amphetamines === Amphetamines are a chemical class of stimulants, entactogens, hallucinogens, and other drugs. They feature a phenethylamine core with a methyl group attached to the alpha carbon resulting in amphetamine, along with additional substitutions.
Sources: en.wikipedia.org
Ground calcium carbonate is an abrasive (both as scouring powder and as an ingredient of household scouring creams), in particular in its calcite form, which has the relatively low hardness level of 3 on the Mohs scale, and will therefore not scratch glass and most other ceramics, enamel, bronze, iron, and steel, and have a moderate effect on softer metals like aluminium and copper. A paste made from calcium carbonate and deionized water can be used to clean tarnish on silver.
Supportive measures may be instituted prior to surgery. These measures include fluid resuscitation. Intravenous opioids can be used for pain control. Antibiotics are often not needed. In cases of severe inflammation, shock, or if the person has higher risk for general anesthesia (required for cholecystectomy), an interventional radiologist may insert a percutaneous drainage catheter into the gallbladder (percutaneous cholecystostomy tube) and treat the person with antibiotics until the acute inflammation resolves. A cholecystectomy may then be warranted if the person's condition improves. Homeopathic approaches to treating cholecystitis have not been validated by evidence and should not be used in place of surgery.
Despite this toxicity, consumption of heavy water under normal circumstances does not pose a health threat to humans. It is estimated that a 70 kg (154 lb) person might drink 4.8 litres (1.3 US gal) of heavy water without serious consequences. Small doses of heavy water (a few grams in humans, containing an amount of deuterium comparable to that normally present in the body) are routinely used as harmless metabolic tracers in humans and animals.
Thebacon (INN; pronounced ), or dihydrocodeinone enol acetate, is a semisynthetic opioid that is similar to hydrocodone and is most commonly synthesised from thebaine. Thebacon was invented in Germany in 1924, four years after the first synthesis of hydrocodone. Thebacon is a derivative of acetyldihydrocodeine, where only the 6–7 double bond is saturated. Thebacon is marketed as its hydrochloride salt under the trade name Acedicon, and as its bitartrate under Diacodin and other trade names. The hydrochloride salt has a free base conversion ratio of 0.846. Other salts used in research and other settings include thebacon's phosphate, hydrobromide, citrate, hydroiodide, and sulfate.
=== seg-seo === seganserin (INN) seglitide (INN) Sehippy seladelpar (INN) selamectin Selarsdi Selax Seldane Selecor Select 1/35 Selectol selegiline (INN) selenomethionine (75 Se) (INN) Selepen selepressin (INN) Selestoject seletracetam (USAN, (INN)) selexipag (INN) selfotel (INN) seliciclib (INN) selodenoson (USAN) Selpak selprazine (INN) Selsun Selsun Blue seltraposin (INN) selumetinib (USAN) selurampanel (INN) selvacovatein (INN) semagacestat (USAN, INN) semaglutide (INN) sematilide (INN) semduramicin (INN) Semicid Semilente semorphone (INN) semotiadil (INN) semparatide (INN) Semprex-D semuloparin (USAN, INN) semustine (INN) Senexon senicapoc (USAN) Sennatural senofilcon A (USAN) Senokot Senolax Sensipar Sensorcaine Senvelgo seocalcitol (INN)
Sources: en.wikipedia.org
Nanotechnology provides methods to organizing materials such as molecules, polymers, building blocks, etc. to form precise nanostructures which have many applications. In the process and application of peptide self-assembly into nano tubes, the single-wall carbon nano tubes is an example which consists of a graphene sheet seamlessly wrapped to a cylinder. This produced in the outside flow of a carbon and yield by laser vaporization of graphite enriched by a transition metal. Nanoimprint lithography is a popular method to fabricate nanometer scale pattern. The patterns are made by mechanical deformation of imprint resist (monomer or polymer formulation) and subsequent processes. Then, it is cured by heat or ultraviolet light, and tight level of the resist and template is controlled at appropriate conditions depend on our purposes. In addition, nanoimprint lithography has high resolution and throughput with low cost. Disadvantages include increased time for templating procedures, a lack of standard procedures results in multiple fabrication methods, and the patterns that are able to be formed are limited.
=== Ca === Mary Letitia Caldwell (1890–1972), American chemist who developed a method for purifying crystalline porcine pancreatic amylase Melvin Calvin (1911–1997), American chemist, winner of 1961 Nobel Prize in Chemistry Allison A. Campbell (born 1963), American chemist studying biomineralization, biomimetics and biomaterials Constantin Cândea (1887–1971), Romanian analytical chemist who studied methods of separating metals Stanislao Cannizzaro (1826–1910), Italian chemist, postulated the Cannizzaro reaction María Luz Cárdenas (born 1944). Chilean-French enzymologist known for work on mammalian hexokinases. Heinrich Caro (1834–1910), German chemist who developed a synthesis for aniline red and other dyes Wallace Carothers (1896–1937), American chemist, known for the discovery of nylon Emma P. Carr (1880–1972), American chemist known for work on unsaturated hydrocarbons and absorption spectra Marjorie Constance Caserio (1929–2021), American chemist, known for Basic Principles of Organic Chemistry, winner of the Garvan Medal Martina Casiano y Mayor (1881–1958), Spanish chemist and teacher, first female member of the Spanish Society of Physics and Chemistry Marta Catellani (PhD 1971), Italian chemist working on palladium as a catalyst for multistep organic reactions, who discovered the Catellani reaction Henry Cavendish (1731–1810), British experimental and theoretical chemist and physicist noted for the discovery of hydrogen
Treatment options for idiopathic pulmonary fibrosis are very limited, since no current treatment has stopped the progression of the disease. Because of this, there is no evidence that any medication can significantly help this condition, despite ongoing research trials. However, current treatment options such as pirfenidone and nintedanib can help slow progression of idiopathic pulmonary fibrosis, the most common form of pulmonary fibrosis. Lung transplantation is the only therapeutic option available in severe cases. A lung transplant can improve the patient's quality of life. Immunosuppressive drugs can also be considered. These are sometimes prescribed to slow the processes that lead to fibrosis. Some types of lung fibrosis respond to corticosteroids, such as prednisone. Oxygen therapy is also an option. The patient may choose how much oxygen to use. The use of oxygen doesn't repair the lung damage, but can: make breathing and exercise easier; prevent or lessen complication from low blood oxygen levels; reduce blood pressure; and improve sleep and sense of well-being. The immune system is thought to play a central role in the development of many forms of pulmonary fibrosis. The goal of treatment with immunosuppressive agents such as corticosteroids is to decrease lung inflammation and subsequent scarring. Responses to treatment vary. Those whose conditions improve with immunosuppressive treatment probably do not have idiopathic pulmonary fibrosis, for idiopathic pulmonary fibrosis has no significant treatment or cure.
=== Stimulation and rising phase === A typical action potential begins at the axon hillock with a sufficiently strong depolarization, e.g., a stimulus that increases Vm. This depolarization is often caused by the injection of extra sodium cations into the cell; these cations can come from a wide variety of sources, such as chemical synapses, sensory neurons or pacemaker potentials. For a neuron at rest, there is a high concentration of sodium and chloride ions in the extracellular fluid compared to the intracellular fluid, while there is a high concentration of potassium ions in the intracellular fluid compared to the extracellular fluid. The difference in concentrations, which causes ions to move from a high to a low concentration, and electrostatic effects (attraction of opposite charges) are responsible for the movement of ions in and out of the neuron. The inside of a neuron has a negative charge, relative to the cell exterior, from the movement of K+ out of the cell. The neuron membrane is more permeable to K+ than to other ions, allowing this ion to selectively move out of the cell, down its concentration gradient. This concentration gradient along with potassium leak channels present on the membrane of the neuron causes an efflux of potassium ions making the resting potential close to EK ≈ −75 mV. Since Na+ ions are in higher concentrations outside of the cell, the concentration and voltage differences both drive them into the cell when Na+ channels open.
== Sierra Leone == Amadu Wurie - Educationist and politician, First Minister of Education and later Minister of Interior of Sierra Leone Sir Banja Tejan-Sie - Politician and lawyer. former vice president under SLPP (1953–1956), former chief justice and Governor-General of Sierra Leone Mohamed Juldeh Jalloh – Current vice president, Republic of Sierra Leone Abass Bundu – Current Speaker of Parliament Sierra Leone, former minister of foreign affairs, former Executive Secretary of the Economic Community of West African States Ibrahim Bundu - former majority leader of the Sierra Leone Parliament, Sierra Leone Abdulai Hamid Charm - former chief justice, Sierra Leone Umu Hawa Tejan-Jalloh – former chief justice, Diplomat, Sierra Leone Miatta Maria Samba - Sierra Leonian jurist and current judge at the International Criminal Court (ICC). Sulaiman Tejan-Jalloh – politician and Diplomat, former Minister of Transport and Communications and former ambassador to US, Sierra Leone Neneh Cherry (birth name Neneh Mariann Karlsson) – Singer-songwriter, rapper, occasional DJ and broadcaster, Sweden Titiyo (birth name Titiyo Yambalu Felicia Jah) – singer and songwriter, Sweden Alpha Timbo – Politician, educationist, lecturer and trade unionist. Minister of Primary and Secondary Education, former Minister of Labor and Industrialization, Sierra Leone Chernor Bah - Minister of Information and Civic Education Chernor Maju Bah – lawyer and politician.
Sources: en.wikipedia.org
Standard practice is a desiccated container at −20 °C, protected from light and kept sealed between uses. Letting the vial reach room temperature before opening reduces condensation on the powder. Repeated warming and cooling of the whole container is generally avoided.
There is no broadly accepted figure for TB-500. Laboratory practice is short-term storage at 2–8 °C with longer-term aliquots frozen, and degradation is expected to increase with time and temperature. Users typically rely on their own stability checks rather than published data.
Mass measurement provides the clearest confirmation by matching an observed value to the expected one. Reversed-phase chromatography adds a purity estimate through peak integration. Combining both is standard because neither alone establishes identity and purity together.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.